Back to Search Start Over

Biochemically deleterious human NFKB1 variants underlie an autosomal dominant form of common variable immunodeficiency.

Authors :
Li J
Lei WT
Zhang P
Rapaport F
Seeleuthner Y
Lyu B
Asano T
Rosain J
Hammadi B
Zhang Y
Pelham SJ
Spaan AN
Migaud M
Hum D
Bigio B
Chrabieh M
Béziat V
Bustamante J
Zhang SY
Jouanguy E
Boisson-Dupuis S
El Baghdadi J
Aimanianda V
Thoma K
Fliegauf M
Grimbacher B
Korganow AS
Saunders C
Rao VK
Uzel G
Freeman AF
Holland SM
Su HC
Cunningham-Rundles C
Fieschi C
Abel L
Puel A
Cobat A
Casanova JL
Zhang Q
Boisson B
Source :
The Journal of experimental medicine [J Exp Med] 2021 Nov 01; Vol. 218 (11). Date of Electronic Publication: 2021 Sep 02.
Publication Year :
2021

Abstract

Autosomal dominant (AD) NFKB1 deficiency is thought to be the most common genetic etiology of common variable immunodeficiency (CVID). However, the causal link between NFKB1 variants and CVID has not been demonstrated experimentally and genetically, and there has been insufficient biochemical characterization and enrichment analysis. We show that the cotransfection of NFKB1-deficient HEK293T cells (lacking both p105 and its cleaved form p50) with a κB reporter, NFKB1/p105, and a homodimerization-defective RELA/p65 mutant results in p50:p65 heterodimer-dependent and p65:p65 homodimer-independent transcriptional activation. We found that 59 of the 90 variants in patients with CVID or related conditions were loss of function or hypomorphic. By contrast, 258 of 260 variants in the general population or patients with unrelated conditions were neutral. None of the deleterious variants displayed negative dominance. The enrichment in deleterious NFKB1 variants of patients with CVID was selective and highly significant (P = 2.78 × 10-15). NFKB1 variants disrupting NFKB1/p50 transcriptional activity thus underlie AD CVID by haploinsufficiency, whereas neutral variants in this assay should not be considered causal.<br />Competing Interests: Disclosures:   S.J. Pelham became employed at Takeda UK Ltd. after contributing to this work. B. Grimbacher reported grants from BMBF, DFG, several pharmaceutical companies, and foundations, and personal fees from several pharmaceutical companies outside the submitted work. No other disclosures were reported.<br /> (© 2021 Li et al.)

Details

Language :
English
ISSN :
1540-9538
Volume :
218
Issue :
11
Database :
MEDLINE
Journal :
The Journal of experimental medicine
Publication Type :
Academic Journal
Accession number :
34473196
Full Text :
https://doi.org/10.1084/jem.20210566